Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Centre Oscar Lambret
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Stanford University
National Cancer Institute (NCI)
University of California, San Francisco
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
University of California, Davis
Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc.
Memorial Sloan Kettering Cancer Center
Hoffmann-La Roche
Grupo Espanol de Tumores Neuroendocrinos
National Institute of Cardiology, Warsaw, Poland
Columbia University
Children's Oncology Group
Olivia Newton-John Cancer Research Institute
Exelixis
Ipsen
National Institutes of Health Clinical Center (CC)
Cedars-Sinai Medical Center
Boston Scientific Corporation
University of Florida
National Institutes of Health Clinical Center (CC)
Assistance Publique - Hôpitaux de Paris
Tata Memorial Hospital
University of Alberta
Institut du Cancer de Montpellier - Val d'Aurelle
Jonsson Comprehensive Cancer Center
Institut du Cancer de Montpellier - Val d'Aurelle
Chimeric Therapeutics
SAPU NANO (US) LLC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
University of Nebraska
Guerbet
RayzeBio, Inc.
University of Wisconsin, Madison
IRCCS San Raffaele
Imperial College London
Imperial College London
Imperial College London
M.D. Anderson Cancer Center
Mayo Clinic
Rezolute